Description:

MYO is the ticker symbol for MyoKardia, Inc., a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapies designed to address serious cardiovascular diseases. Listed on the New York Stock Exchange (NYSE), MyoKardia aims to transform the treatment of cardiomyopathies by targeting the underlying causes of these diseases, thereby improving patients' quality of life and reducing the risk of heart failure and sudden death. The company's lead product candidate, mavacamten, has shown promise in treating hypertrophic cardiomyopathy (HCM) and has been a significant focus of its research efforts.

Data:

Yields: